NASDAQ:REGN - Regeneron Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $377.25 +2.45 (+0.65 %) (As of 08/21/2018 01:43 PM ET)Previous Close$375.48Today's Range$374.54 - $377.5052-Week Range$281.89 - $505.49Volume9,598 shsAverage Volume858,003 shsMarket Capitalization$40.44 billionP/E Ratio28.05Dividend YieldN/ABeta1.26 Company ProfileAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Receive REGN News and Ratings via Email Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical SymbolNASDAQ:REGN CUSIP75886F10 Webwww.regeneron.com Phone914-847-7000 Debt Debt-to-Equity Ratio0.10 Current Ratio3.62 Quick Ratio2.92 Price-To-Earnings Trailing P/E Ratio28.05 Forward P/E Ratio19.70 P/E Growth1.27 Sales & Book Value Annual Sales$5.87 billion Price / Sales6.94 Cash Flow$15.9852 per share Price / Cash23.60 Book Value$57.09 per share Price / Book6.61 Profitability EPS (Most Recent Fiscal Year)$13.41 Net Income$1.20 billion Net Margins25.65% Return on Equity29.30% Return on Assets20.66% Miscellaneous Employees6,200 Outstanding Shares108,060,000Market Cap$40.44 billion Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions What is Regeneron Pharmaceuticals' stock symbol? Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN." How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals Inc (NASDAQ:REGN) issued its quarterly earnings results on Thursday, August, 2nd. The biopharmaceutical company reported $5.45 earnings per share for the quarter, topping analysts' consensus estimates of $4.60 by $0.85. The biopharmaceutical company had revenue of $1.61 billion for the quarter, compared to analyst estimates of $1.56 billion. Regeneron Pharmaceuticals had a return on equity of 29.30% and a net margin of 25.65%. The business's revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.17 EPS. View Regeneron Pharmaceuticals' Earnings History. When is Regeneron Pharmaceuticals' next earnings date? Regeneron Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for Regeneron Pharmaceuticals. What price target have analysts set for REGN? 22 equities research analysts have issued 1-year target prices for Regeneron Pharmaceuticals' stock. Their predictions range from $305.00 to $566.00. On average, they anticipate Regeneron Pharmaceuticals' share price to reach $419.7727 in the next year. This suggests a possible upside of 11.7% from the stock's current price. View Analyst Price Targets for Regeneron Pharmaceuticals. What is the consensus analysts' recommendation for Regeneron Pharmaceuticals? 22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 14 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Regeneron Pharmaceuticals. What are Wall Street analysts saying about Regeneron Pharmaceuticals stock? Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock: 1. According to Zacks Investment Research, "The performance of Regeneron's key growth driver, Eylea, is impressive and the potential label expansion of Eylea in patients with wet age-related macular degeneration will further boost sales. Meanwhile, Dupixent uptake in the United States for moderate-to-severe atopic dermatitis was encouraging and a label expansion of the drug will further boost sales. However, the company is heavily dependent on Eylea for growth. Investors are cautious as the company had earlier suffered setback when it decided not to advance the nesvacumab and Eylea combination study to phase III development after two phase II studies evaluating the combination therapy failed to show additional benefit over Eylea monotherapy in patients with diabetic macular edema or wet age-related macular degeneration. Any setbacks will adversely hurt the stock. Shares have underperofrmed the industry in the last six months." (7/3/2018) 2. Canaccord Genuity analysts commented, "We are encouraged by better US Dupixent growth, but recognize that the pediatric atopic dermatitis market will be the core growth driver, with approval expected around 2021. Also, while we understand that REGN and investors are focusing more on Dupixent’s growth than EYLEA’s, the lack of EYLEA guidance going forward is concerning. REGN cannot give guidance on Dupixent since Sanofi books the revenues, and EYLEA is still expected to be the core revenue driver for REGN." (2/7/2018) Who are some of Regeneron Pharmaceuticals' key competitors? Some companies that are related to Regeneron Pharmaceuticals include AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Sanofi (SNY), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), AstraZeneca (AZN), Bayer (BAYRY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS) and ASTELLAS PHARMA/ADR (ALPMY). Who are Regeneron Pharmaceuticals' key executives? Regeneron Pharmaceuticals' management team includes the folowing people: Dr. Leonard S. Schleifer, Co-Founder, Pres, CEO & Exec. Director (Age 65)Dr. George D. Yancopoulos, Pres, Chief Scientific Officer & Director (Age 58)Mr. Robert E. Landry Jr., Sr. VP of Fin. & CFO (Age 54)Dr. Neil Stahl, Exec. VP of R&D (Age 61)Mr. Daniel P. Van Plew, Exec. VP and Gen. Mang. of Industrial Operations & Product Supply (Age 45) Has Regeneron Pharmaceuticals been receiving favorable news coverage? News coverage about REGN stock has been trending positive on Tuesday, according to Accern Sentiment. Accern rates the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Regeneron Pharmaceuticals earned a media and rumor sentiment score of 0.33 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 46.40 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Regeneron Pharmaceuticals. Who are Regeneron Pharmaceuticals' major shareholders? Regeneron Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include SANOFI (95.60%), BlackRock Inc. (5.56%), FMR LLC (3.98%), Janus Henderson Group PLC (1.67%), Polen Capital Management LLC (1.38%) and American Century Companies Inc. (0.85%). Company insiders that own Regeneron Pharmaceuticals stock include Arthur F Ryan, Charles A Baker, George L Sing, Joseph L Goldstein, Michael S Aberman, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry, Robert J Terifay and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals. Which institutional investors are selling Regeneron Pharmaceuticals stock? REGN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Orbimed Advisors LLC, Point72 Asset Management L.P., Summit Trail Advisors LLC, Massachusetts Financial Services Co. MA, Millennium Management LLC, Russell Investments Group Ltd. and Bank of Montreal Can. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Charles A Baker, George L Sing, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Sanofi. View Insider Buying and Selling for Regeneron Pharmaceuticals. Which institutional investors are buying Regeneron Pharmaceuticals stock? REGN stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Canada Pension Plan Investment Board, Cornerstone Wealth Management LLC, Assenagon Asset Management S.A., Polen Capital Management LLC, First Trust Advisors LP, Worldquant Millennium Quantitative Strategies LLC and Cannell Peter B & Co. Inc.. View Insider Buying and Selling for Regeneron Pharmaceuticals. How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Regeneron Pharmaceuticals' stock price today? One share of REGN stock can currently be purchased for approximately $375.81. How big of a company is Regeneron Pharmaceuticals? Regeneron Pharmaceuticals has a market capitalization of $40.44 billion and generates $5.87 billion in revenue each year. The biopharmaceutical company earns $1.20 billion in net income (profit) each year or $13.41 on an earnings per share basis. Regeneron Pharmaceuticals employs 6,200 workers across the globe. How can I contact Regeneron Pharmaceuticals? Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected] MarketBeat Community Rating for Regeneron Pharmaceuticals (NASDAQ REGN)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 1,119 (Vote Outperform)Underperform Votes: 915 (Vote Underperform)Total Votes: 2,034MarketBeat's community ratings are surveys of what our community members think about Regeneron Pharmaceuticals and other stocks. Vote "Outperform" if you believe REGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REGN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/21/2018 by MarketBeat.com StaffFeatured Article: Do Tariffs Work?